Vanda Pauses Anxiety Drug After Trial Fails
Vanda Pharmaceuticals paused its experimental anxiety drug program after the treatment failed to meet the main goal in a late-stage study. Company shares fell following the news.
Xurve View
Insights:
Xurve View
Vanda Pharmaceuticals Inc halted its experimental anxiety drug program after failing the primary efficacy goal in a late-stage trial, sending shares down 17% in extended trading on Wednesday evening. The setback halts development for VQW-765 following disappointing data from a 546-patient trial. Investors face renewed uncertainty over the company's clinical pipeline diversification.
